March 08, 2012 07:33 PM Eastern Daylight Time
Bristol-Myers Squibb Posts Data Update on Daclatasvir, an NS5A Inhibitor in Phase III Development for the Treatment of Hepatitis C
PRINCETON, N.J.--()--Bristol-Myers Squibb Company (NYSE:BMY) today posted an overview of new data on daclatasvir (or BMS-790052) on the company website. Daclatasvir is an NS5A replication complex inhibitor in Phase III development for the treatment of hepatitis C. These data were presented Thursday, March 8, at the Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.